{
    "nctId": "NCT00237198",
    "briefTitle": "Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment",
    "officialTitle": "Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Postmenopausal Women With Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 47,
    "primaryOutcomeMeasure": "Safety during treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with histologically or cytologically documented breast cancer\n* Patients with progressive breast cancer (advanced breast cancer, locoregional recurrence not operative, or metastatic breast cancer)\n* Patients with hormone receptor (ER and/or PgR) positive or both unknown.\n* Postmenopausal patients between ages 20 and 79 years, inclusive\n* Patients with a history of adjuvant therapy or advanced breast cancer treated with anti-estrogens\n* Patients with documented measurable or evaluable lesions.\n* Patients with sufficient organ function to evaluate the safety\n* Patients whose performance status (PS) is 0\uff5e2\n\nExclusion Criteria:\n\n* Patients with diffuse lymphangitis carcinomatosa of the lung or CNS involvement, liver metastasis occupying more than one third of the liver, or inflammatory breast cancer\n* Patients with other concurrent or previous malignant disease (excluding contralateral breast cancer, in situ carcinoma of cervix uteri, and adequately treated basal or squamous cell carcinoma of the skin)\n* Patients in whom one of the following is the sole manifestation of disease: hilar enlargement, pleural effusion and ascites\n* Patients with only blastic bone metastases or a mixed blastic and lytic bone metastases at the same site and no other measurable or evaluable lesions\n* Patients with serious current disease such as uncontrolled cardiac diseases and/or uncontrolled diabetes mellitus by any medications (including a historical serious cardiac disease)\n* Patients with adrenal insufficiency (treated or untreated) or Cushing's syndrome\n* Patients with any of the following previous treatments\n\n  1. Chemotherapy for metastatic and/or locoregional recurrent disease\n  2. Previous adjuvant endocrine therapy other than ovariectomy, anti-estrogen treatment, LH-RH analogues or radiation castration\n  3. Previous first-line endocrine therapy (e.g., aromatase inhibitors and gastagens) for the treatment of metastatic and/or locoregional recurrent breast cancer other than anti-estrogen or LH-RH analogues treatment\n  4. Patients who have not recovered from toxicity caused by previous therapy\n  5. For patients on investigational drugs, adequate wash-out periods of at least 7 days in the case of topical investigational drugs and at least 30 days in the case of systemic\n  6. Previous bisphosphonate therapy started within 6 months without any other measurable or evaluable lesions\n  7. Patients who have not stopped treatment with other anti-estrogen or anti-cancer drugs (other than bisphosphonates) before starting the trial medication\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}